This profile was last updated on .
Is this you? Claim your profile.
+ Get 10 Free Contacts a Month
Please agree to the terms and conditions
European Society of Cardiology
In May 2016, the company announced that 1-year data confirming long-term safety from the BIOSOLVE-II trial were presented by Prof. Haude at the EuroPCR 2016 conference and concurrently published online by Prof. Haude, et al in the European Heart Journal.
In the company's press release, Prof. Haude commented, "Now that clinical results have firmly established the safety and clinical performance of Magmaris, the magnesium-based scaffold could emerge as a strong alternative to currently available polymer-based scaffolds.
Because it is made of magnesium, the scaffold has some unique advantages over polymer-based options in terms of deliverability and radial resistance following the implantation procedure.
According to Biotronik, the study established the safety and clinical performance of the Magmaris device.
Dr. Haude commented in the company's press release, "These results offer the first confirmation of Magmaris' longer-term safety and efficacy.
BIOSOLVE-II demonstrates a promising potential of a magnesium-based approach to treating coronary artery disease as an alternative to polymer-based bioresorbable scaffolds.
BIOTRONIK - Noticias - Comunicados de Prensa
Esri Deutschland Group
Bass Pro Shops